ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

40.53
0.23
(0.57%)
Closed January 20 4:00PM
40.85
0.32
(0.79%)
After Hours: 7:58PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
40.85
Bid
37.50
Ask
49.10
Volume
1,387,301
40.45 Day's Range 41.55
36.52 52 Week Range 91.10
Market Cap
Previous Close
40.30
Open
41.39
Last Trade Time
Financial Volume
$ 56,652,105
VWAP
40.8362
Average Volume (3m)
1,810,790
Shares Outstanding
85,353,479
Dividend Yield
-
PE Ratio
-35.89
Earnings Per Share (EPS)
-1.8
Revenue
371.21M
Net Profit
-153.61M

About CRISPR Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specifi... CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Zug, Che
Founded
-
CRISPR Therapeutics AG is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CRSP. The last closing price for CRISPR Therapeutics was $40.30. Over the last year, CRISPR Therapeutics shares have traded in a share price range of $ 36.52 to $ 91.10.

CRISPR Therapeutics currently has 85,353,479 shares outstanding. The market capitalization of CRISPR Therapeutics is $3.44 billion. CRISPR Therapeutics has a price to earnings ratio (PE ratio) of -35.89.

CRISPR Therapeutics (CRSP) Options Flow Summary

Overall Flow

Bearish

Net Premium

-8M

Calls / Puts

40.00%

Buys / Sells

63.64%

OTM / ITM

16.67%

Sweeps Ratio

0.00%

CRSP Latest News

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

-Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with...

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company...

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.681.692805576340.1741.0736.52199142039.24422219CS
40.761.8957345971640.0944.2836.52175996540.24019075CS
12-7.08-14.771541831847.9359.069336.52181079046.24739707CS
26-20.29-33.18613019361.1463.389936.52140956147.56537169CS
52-21.4-34.377510040262.2591.136.52148531857.30037944CS
156-25.66-38.580664561766.5191.136.52150113758.44751369CS
260-19.28-32.063861633160.13220.2132144421778.30711291CS

CRSP - Frequently Asked Questions (FAQ)

What is the current CRISPR Therapeutics share price?
The current share price of CRISPR Therapeutics is $ 40.85
How many CRISPR Therapeutics shares are in issue?
CRISPR Therapeutics has 85,353,479 shares in issue
What is the market cap of CRISPR Therapeutics?
The market capitalisation of CRISPR Therapeutics is USD 3.44B
What is the 1 year trading range for CRISPR Therapeutics share price?
CRISPR Therapeutics has traded in the range of $ 36.52 to $ 91.10 during the past year
What is the PE ratio of CRISPR Therapeutics?
The price to earnings ratio of CRISPR Therapeutics is -35.89
What is the cash to sales ratio of CRISPR Therapeutics?
The cash to sales ratio of CRISPR Therapeutics is 14.85
What is the reporting currency for CRISPR Therapeutics?
CRISPR Therapeutics reports financial results in USD
What is the latest annual turnover for CRISPR Therapeutics?
The latest annual turnover of CRISPR Therapeutics is USD 371.21M
What is the latest annual profit for CRISPR Therapeutics?
The latest annual profit of CRISPR Therapeutics is USD -153.61M
What is the registered address of CRISPR Therapeutics?
The registered address for CRISPR Therapeutics is BAARERSTRASSE 14, ZUG, 6300
What is the CRISPR Therapeutics website address?
The website address for CRISPR Therapeutics is www.crisprtx.com
Which industry sector does CRISPR Therapeutics operate in?
CRISPR Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTCTBTC Digital Ltd
$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
$ 29.97
(45.98%)
19.09M
GSITGSI Technology
$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
$ 137.71
(3.10%)
201.4M

CRSP Discussion

View Posts
jondoeuk jondoeuk 6 days ago
Anticipated 2025 milestones https://www.globenewswire.com/news-release/2025/01/13/3008308/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2025-Milestones.html
👍️ 1
jondoeuk jondoeuk 6 days ago
Link to the webcast https://jpmorgan.metameetings.net/events/healthcare25/sessions/58421-crispr-therapeutics/webcast/general_signin?gpu_only=true&kiosk=true+%5Bjpmorgan.metameetings.net%5D
👍️ 1
jondoeuk jondoeuk 2 weeks ago
They will present at the 43rd Annual J.P. Morgan Healthcare Conference (Jan 14, at 2:15 PM PST).
👍️ 1
PonkenPlonken PonkenPlonken 1 month ago
cheap cheap
👍️ 1
jondoeuk jondoeuk 1 month ago
The PR https://www.globenewswire.com/news-release/2024/12/09/2993974/0/en/CRISPR-Therapeutics-Presents-Data-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html

Poster https://ir.crisprtx.com/static-files/12114290-21a6-4544-9cb7-de4fe2852e94
👍️0
PonkenPlonken PonkenPlonken 2 months ago
Neglected ugly duckling. $NTLA, $VERV & $CRBU now do trials outside of the US.... Maybe sentiment change is on the horizon -- see below

"The CBER director also apologized for “mistakes” in how the FDA handled early work for in vivo gene therapies, which “led to offshoring of some of the trials.”"
https://endpts.com/fda-vaccine-chief-peter-marks-pledges-to-stay-as-long-as-hes-welcome/#:~:text=The%20CBER%20director%20also%20apologized,%E2%80%9Cit%20is%20really%20important.%E2%80%9D

CHEAP CHEAP
SRPT and BMS announcing nice CRISPR deals with ARWR and PRME should help this too!
👍️0
jondoeuk jondoeuk 2 months ago
CTX130 data in R/R T-cell lymphomas (peripheral T-cell lymphoma or cutaneous T-cell lymphoma) https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00508-4/abstract

The ORR was 46.2%. Of those treated at DL3 and higher, the ORR was 51.6%.
👍️ 1
PonkenPlonken PonkenPlonken 2 months ago
so so so undervalued and misunderstood i believe...... frankly just cheap
https://x.com/RNAiAnalyst/status/1859876294487363651
👍️ 1
jondoeuk jondoeuk 2 months ago
They now have the ability to put in eight to nine edits. So it is a single cassette that expresses the CAR, can express a cytokine and has an shRNA-like approach to knock down genes. So there's no theoretical limit as to the number of edits, but there may be marginal utility beyond a certain point.

Hopefully, they look to improve donor selection, cell selection and manufacturing, as all could increase efficacy.
👍️ 1
jondoeuk jondoeuk 2 months ago
ASH abstract https://ash.confex.com/ash/2024/webprogram/Paper203563.html
👍️0
jondoeuk jondoeuk 2 months ago
Q3 business update and financial results https://www.globenewswire.com/news-release/2024/11/05/2974996/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2024-Financial-Results.html
👍️0
Monksdream Monksdream 3 months ago
CRSP 10Q 11/5
👍️0
Monksdream Monksdream 3 months ago
CRSP under $50
👍️0
jondoeuk jondoeuk 3 months ago
OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082
👍️ 1
TechandBio TechandBio 4 months ago
CRSP will climb tremendously over the years.
SMMT went from $1.00-30.00+ this year cancer drug superior to Mercks Keytruda
ICCM company being over looked that kills cancers by freezing them 97% non recurrence rate for breast cancer after 5 years and superior data to lung cancer safe cryoblation is done in less than hour.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html
👍️0
Monksdream Monksdream 4 months ago
Buy range again thanks a bunch
👍️0
Monksdream Monksdream 4 months ago
Buy range again thanks a bunch
👍️0
OldAIMGuy OldAIMGuy 4 months ago
Hi MD,
Here's a little longer view:


This might also be a cyclical low here. But, most of 2024 has shown severe distribution of shares until about the last month. That, at least, seems to be flattening out.
Best wishes,
OAG
👍️0
Monksdream Monksdream 4 months ago
CRSP trend since February remains bearish
👍️0
jondoeuk jondoeuk 6 months ago
Q2 results https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200100452.html
👍️0
lambchops lambchops 6 months ago
Hey Monk, Hopefully you bought some shares on Friday@ Sold at 10% discount!

LC

CRISPR!!!
👍️0
Monksdream Monksdream 6 months ago
CRSP under $75
👍️0
TechandBio TechandBio 6 months ago
Crispr added some $120 Vertical debit spreads in 2026

$CRSP
👍️ 1
axelvento axelvento 8 months ago
I agree.....solid company$$$$$$$$
👍️0
Monksdream Monksdream 8 months ago
It may take some time for CRSP returns to a $200 price tag
The same could be said for hundreds of other stocks that soared during Covid mania
Since then the stock has rallied from low points
With all that money the company has to do incredible things with its biotechnology the stock isn’t going to zero
👍️ 1
axelvento axelvento 8 months ago
Strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024

https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html
👍️0
jondoeuk jondoeuk 8 months ago
(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.
👍️0
jondoeuk jondoeuk 8 months ago
Business Update and Q1 Financial Results https://uk.finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000300.html
👍️0
jondoeuk jondoeuk 8 months ago
Highlights (plus new programs utilising in vivo gene editing) https://finance.yahoo.com/news/crispr-therapeutics-highlights-asgct-oral-110000066.html
👍️0
jondoeuk jondoeuk 9 months ago
https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html

EDIT is also pursuing myocilin-related glaucoma https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html
👍️0
OldAIMGuy OldAIMGuy 9 months ago
StockCharts 3 year history with 20% ZigZag reversals................



CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG
👍️0
OldAIMGuy OldAIMGuy 9 months ago
Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG
👍️0
Monksdream Monksdream 9 months ago
CRSP over $30
👍️0
jondoeuk jondoeuk 10 months ago
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html
👍️0
Monksdream Monksdream 11 months ago
CRSP new 52 week high
👍️0
Monksdream Monksdream 11 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 11 months ago
CRSP new 52 week high
👍️ 1
Monksdream Monksdream 11 months ago
CRSP new 52 week high
👍️ 1
jondoeuk jondoeuk 11 months ago
They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html
👍️0
jondoeuk jondoeuk 11 months ago
EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html
👍️ 1
Monksdream Monksdream 11 months ago
Didn’t tank like BLUE
Recovered


More analysis from Nanolyze

👍️0
Monksdream Monksdream 12 months ago
So there has been some discussion since my last post
More in this podcast
🌈 1 🍆 1
jondoeuk jondoeuk 1 year ago
Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html
👍️ 1
jondoeuk jondoeuk 1 year ago
Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html
👍️0
jondoeuk jondoeuk 1 year ago
Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true
👍️ 1
jondoeuk jondoeuk 1 year ago
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html
👍️0
JJ8 JJ8 1 year ago
Good morning OAG,

Surprising and interesting. Share price sudden "jack-rabbit" moves in quick price reversals. The technical picture for today changed from positive breakout yesterday to "High Pole Warning" with sudden drop in price. Apparently the dominating group of participants seem to dictate this pace a bit unusual and different from other stocks. Yet it offers opportunity for profit once one has a good plan and strategy.

Good you have a plan and strategy for your preferred limits and ranges for your trading. Let's see how it goes. Have fun & GLTY
👍️ 1
OldAIMGuy OldAIMGuy 1 year ago
Good morning JJ8,

It needs to crest $85 or better to get me interested in reducing my share inventory. A drop to $57 will trigger an addition of 12% to share count.

I'd like to see it crest $72 and maintain that price right now.

Best wishes,
OAG
👍️0
JJ8 JJ8 1 year ago
CRSP share price Double Top Breakout today on 19-Dec-2023. Happy Holidays & GLTA
👍️0
Monksdream Monksdream 1 year ago
Oscar Wilde once observed that a cynic knows the price of everything and the value of nothing
👍️0

Your Recent History

Delayed Upgrade Clock